Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: Arachidonyl ethanolamide (AEA) is an endogenous lipid neurotransmitter with cannabinergic activity, binding to both the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. Fatty acid amide hydrolase (FAAH) is the enzyme responsible for the hydrolysis and inactivation of AEA. Metabolism of AEA by cyclooxygenase-2, leading to formation of prostaglandin ethanolamides, and by lipoxygenases has also been documented. (±)5(6)-EET ethanolamide is a cytochrome P450 (CYP450) metabolite of AEA, although specific stereochemistry rather than a racemic mixture ensues from enzymatic metabolism. (±)5(6)-EET ethanolamide is a potent and selective agonist of CB2 (Ki = 8.9 nM for CB2, 11.4 µM for CB1), effectively suppressing forskolin-stimulated accumulation of cAMP through this Gi-coupled receptor (IC50 = 9.8 nM).
(±)5(6)-EET ethanolamide is supplied as a solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as DMSO and dimethyl formamide purged with an inert gas can be used. The solubility of (±)5(6)-EET ethanolamide in these solvents is approximately 20 mg/ml. (±)5(6)-EET ethanolamide is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, the ethanolic solution of (±)5(6)-EET ethanolamide should be diluted with the aqueous buffer of choice. (±)5(6)-EET ethanolamide has a solubility of approximately 0.5 mg/ml in a 1:6 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Felder, C.C., Briley, E.M., Axelrod, J., et al. Proc. Natl. Acad. Sci. USA 90, 7656-7660 (1993).
Lambert, D.M. and Fowler, C.J. J. Med. Chem. 48(16), 5059-5087 (2005).
Deutsch, D.G., Ueda, N., and Yamamoto, S. Prostaglandins Leukot. Essent. Fatty Acids 66(2&3), 201-210 (2002).